Pasar al contenido principal

MODULACION DE LA FUNCION INMUNE EN CANCER DE MAMA METASTATICO HORMONOSENSIBLE TRATADO CON INHIBIDORES DE CDK4/6: IDENTIFICATIÓN DE FACTORS PREDICTIVOS Y NUEVAS ESTRATEGIAS TERAPEUTICAS

PI21/00642

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Bernat-Peguera, Adrià|||0000-0002-3108-0571
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Romeo, Margarita|||0000-0003-1725-8115
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and certain solid tumours, although with controversial data. Here, we evaluate SAMHD1 function in ovarian cancer, both in vitro and in ovarian cancer patients. SAMHD1 expression was downregulated in ovarian cancer cell lines OVCAR3 and SKOV3 by RNA interference. Gene and protein expression changes in immune signalling pathways were assessed. SAMHD1 expression in ovarian cancer patients was evaluated by immunohistochemistry and survival analysis was performed according to SAMHD1 expression. SAMHD1 knockdown induced a significant upregulation of proinflammatory cytokines concomitant to increased expression of the main RNA-sensors, MDA5 and RIG-I, and interferon-stimulated genes, supporting the idea that the absence of SAMHD1 promotes innate immune activation in vitro. To assess the contribution of SAMHD1 in ovarian cancer patients, tumours were stratified in SAMHD1-low and SAMHD1-high expressing tumours, resulting in significantly shorter progression free survival (PFS) and overall survival (OS) in SAMHD1-high expression subgroup (p =0.01 and 0.04, respectively). SAMHD1 depletion correlates with increased innate immune cell signalling in ovarian cancer cells. In clinical samples, SAMHD1-low expressing tumors showed increased progression free survival and overall survival irrespective of BRCA mutation status. These results point towards SAMHD1 modulation as a new therapeutic strategy, able to enhance innate immune activation directly in tumour cells, leading to improved prognosis in ovarian cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Angelats, Laura
  • Esteve, Anna|||0000-0002-1962-971X
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Fernandez, Pedro Luis
  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Pous, Anna
  • Bergamino, Milana|||0000-0002-1091-2711
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Romeo, Marga
  • Teruel, Iris|||0000-0002-5563-6562
  • Mesia, Ricard|||0000-0002-3785-3563
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT. Heterotypic 3D cultures including tumor and immune cells were used to investigate the molecular mechanisms responsible of SAMHD1 depletion through whole transcriptomic profiling, immune infiltration capacity and subsequent delineation of dysregulated immune signaling pathways. SAMHD1 expression was associated to increased risk of recurrence and higher Ki67 levels in post-NACT tumor biopsies of breast cancer patients with residual disease. Survival analysis showed that SAMHD1-expressing tumors presented shorter time-to-progression and overall survival than SAMHD1 negative cases, suggesting that SAMHD1 expression is a relevant prognostic factor in breast cancer. Whole-transcriptomic profiling of SAMHD1-depleted tumors identified downregulation of IL-12 signaling pathway as the molecular mechanism determining breast cancer prognosis. The reduced interleukin signaling upon SAMHD1 depletion induced changes in immune cell infiltration capacity in 3D heterotypic in vitro culture models, confirming the role of the SAMHD1 as a regulator of breast cancer prognosis through the induction of changes in immune response and tumor microenvironment. SAMHD1 expression is a novel prognostic biomarker in early breast cancer that impacts immune-mediated signaling and differentially regulates inflammatory intra-tumoral response. The online version contains supplementary material available at 10.1007/s13402-023-00862-1.